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Background & Aims: Clostridioides difficile infection (CDI) harms a large proportion of 
patients with cirrhosis. Fecal microbiota transplantation (FMT) is recommended for recurrent 
CDI, but its effects in patients with cirrhosis have not been established. We performed a 
multicenter, observational study to evaluate efficacy and safety of FMT for CDI in patients with 
cirrhosis.  
 
Methods: We performed a retrospective study of 63 adults with cirrhosis (median model for end-
stage liver disease score, 14.5; 24 patients with decompensated cirrhosis) who underwent FMT 
for CDI from January 2012 through November 2018 at 8 academic centers in the United States, 
Canada, and Italy. We collected data on patient demographics and characteristics of cirrhosis, 
CDI, and FMT from medical records and compared differences among patients with different 
severities of cirrhosis, and FMT successes vs failures at 8 weeks follow up. We also obtained 
data on adverse events (AE) and severe AEs (SAE) within 12 weeks of FMT. 
 
Results: Patients underwent FMT for recurrent CDI (55/63; 87.3%), severe CDI (6/63; 9.5%), or 
fulminant CDI (2/63; 3.2%) primarily via colonoscopy (59/63; 93.7%) as outpatients (47/63; 
76.8%). FMT success was achieved for 54 patients (85.7%). Among FMT failures, a higher 
proportion used non-CDI antibiotics at time of FMT (44.4% vs 5.6%; P<.001), had Child-Pugh 
scores of B or C (100% vs 37.7%; P<.001), used probiotics (77.8% vs 24.1%, P=.003), had 
pseudomembranes (22.2% vs 0; P=.018), and underwent FMT as inpatients (45.5% vs 19%; 
P=.039), compared with FMT successes. In multivariable analysis, use of non-CDI antibiotics at 
time of FMT (odds ratio, 17.43; 95% CI, 2.00–152.03; P=.01) and use of probiotics (odds ratio, 
11.9; 95% CI, 1.81–78.3; P=.01) were associated with greater risk of FMT failure. FMT-related 
AEs occurred in 33.3% of patients (21/63)—most were self-limited abdominal cramps or 
diarrhea. There were only 5 SAEs that were possibly related to FMT; none involved infection or 
death.  
 
Conclusions: In a retrospective study, we found FMT to be safe and effective for treatment of 
CDI in patients with cirrhosis. 
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Need to Know 
 
Background: Studies are needed to determine outcomes of fecal microbiota transplantation (FMT) 




Findings: This retrospective analysis of data from 63 patients with cirrhosis who underwent 
FMT at 8 centers in 3 countries found that 85.7% were cured of CDI after a single FMT. Severe 
adverse events related to FMT were rare, and none involved infection or death. 
 
Implications for Patient Care: FMT is a safe and effective therapy for patients with cirrhosis 
and CDI.  
 
INTRODUCTION 
 Clostridioides difficile infection (CDI) accounts for nearly 1% of annual hospitalizations 
nationally.1 Patients with cirrhosis are at high risk of CDI due to dysbiosis, functional immunosuppression, 
and frequent antibiotic therapies.2,3 Hospitalized patients with cirrhosis have double the incidence of CDI 
and higher rates of CDI-related complications including mortality and length of stay compared to patients 
without cirrhosis.4,5  
 Fecal microbiota transplantation (FMT) is a recommended treatment option for recurrent CDI 
(RCDI),6 while emerging evidence suggests that FMT is also effective in patients with severe and 
fulminant CDI.7,8 Unfortunately, the FMT Working Group has recommended against FMT use in patients 
with decompensated cirrhosis due to a possible increased risk for adverse events (AEs) based on limited 
evidence.9 Recently, reports of two immunocompromised patients who developed extended spectrum 
beta-lactamase (ESBL) E. coli bacteremia traced to a single donor warned of potential harm associated 
with FMT.10 Overall, rates of adverse events after FMT are low in multiple studies involving 
immunocompromised patients11,12 and patients with cirrhosis who received FMT for hepatic 
encephalopathy (HE).13,14 Unfortunately, even in large studies of FMT for CDI, patients with cirrhosis 
comprise only a small fraction of the study population, limiting the ability to delineate outcomes based on 
liver disease severity or complications, and liver disease-specific medications.15 
The aim of our study was to investigate the rate of CDI cure and safety of FMT in a large, 




PATIENTS AND METHODS 
Patients 
 This is a retrospective observational study involving 8 academic centers in the United States, 
Canada, and Italy. We identified adult patients (age ≥18 years) with cirrhosis who were treated with FMT 
for CDI between January 2012 and November 2018. We excluded patients with <12 weeks follow-up 
(n=1) and those with a history of liver transplantation. The study protocol was approved by the 
institutional review board at each participating center. 
 Patient demographics and characteristics of cirrhosis, CDI, and FMT were extracted from each 
site’s FMT database and medical record. Patient characteristics included age, gender, race, Charlson 
comorbidity score,16 and history of inflammatory bowel disease (IBD). Cirrhosis was characterized by 
etiology, presence of decompensated disease (ascites, HE, hepatorenal syndrome and/or variceal 
hemorrhage), history of cirrhosis-related complications (including ascites, hepatic encephalopathy, 
varices, and variceal hemorrhage), Child-Pugh score, Model for End-Stage Liver Disease (MELD) score, 
pertinent laboratory values at time of FMT (serum sodium concentration, INR, total bilirubin, platelet 
count, white blood cell count, serum creatinine concentration), and use of cirrhosis-related medications 
(lactulose, rifaximin, proton pump inhibitors, prophylactic antibiotics for spontaneous bacterial peritonitis 
(SBP)).  
 Characteristics of CDI included its severity, number of CDI episodes prior to FMT, history of and 
number of CDI-related hospitalizations prior to FMT, non-CDI antibiotic at the time of FMT and within 8 
weeks after FMT (which excluded rifaximin and antibiotics used for SBP prophylaxis), probiotic use at 
time of FMT, and colectomy due to CDI after index FMT. We characterized FMT based on setting of 
delivery (inpatient versus outpatient), donor type (patient directed versus undirected donor), stool type 
(fresh, frozen, lyophilized), delivery method (capsule, colonoscopy, percutaneous gastric tube), and 
presence of pseudomembranous colitis at index FMT.  
Adverse events and severe adverse events (SAE) were documented within 12 weeks of FMT. 




 We classified CDI as recurrent, severe, and/or fulminant as previously described.6 The iagnosis 
of CDI was made based on the appropriate clinical symptoms along with a positive CDI test. Four of our 
sites (accounting for 76.2% of patients) used PCR-based testing for detection of Cl stridioides difficile, 
while the other four utilized PCR or glutamate dehydrogenase combined with toxin enzyme immunoassay. 
FMT success was defined as complete resolution of diarrhea and/or negative stool C. difficile toxin or 
PCR without further need for anti-CDI therapy 8 weeks after a single FMT.17 FMT failure was defined as 
persistent or recurrent diarrhea after a single FMT in conjunction with a positive stool test for C. di ficile 
by toxin EIA or PCR within 8 weeks of FMT. FMT-related diarrhea was defined as self-limited diarrhea 
following administration of FMT, typically resolving within 48-72 hours, without other suspected 
etiologies and without concurrent laboratory evidence of CDI. Immunosuppression was identified in any 
patient with HIV, AIDS-defining illness, inherited or primary immune disorders, treatment with anti-
neoplastic agents, or immunosuppressant medications (including monoclonal antibodies, anti-tumor 
necrosis factor inhibitors, and antimetabolites). 
 AEs were defined as any detrimental medical occurrence in a patient who received FMT, 
including clinically significant changes from the patient’s baseline physical exam, laboratory values, or 
pre-existing conditions. SAEs included any unplanned hospitalizations, life-threatening events, or death. 
These AEs and SAEs were further classified as related or unrelated by the site investigator(s), and by the 
first author (YWC). 
Statistical Analysis 
 The baseline patient, cirrhosis, CDI, and FMT characteristics were described using proportions 
for categorical variables, median and interquartile ranges (IQR) for skewed continuous variables, and 
mean and standard deviation for normally distributed continuous variables. Comparisons of baseline 
patient, cirrhosis, CDI, and FMT characteristics for patients with and without FMT failure at 8 weeks 
were performed using Fisher’s exact test for categorical variables, two-sample t-test for normally 
distributed continuous variables, and Wilcoxon rank sum test for skewed continuous variables.  
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 To determine patient risk factors associated with FMT failure, all baseline characteristics with a 
p-value < 0.25 were placed in a forward stepwise selection model using logistic regression. Due to the 
small sample size, Firth’s penalized logistic regression was used. Final risk factors included those that 
were significant at the 0.05 level. All statistical analysis was performed with SAS version 9.4 (SAS, Cary, 
NC). 
RESULTS 
Patient and CDI characteristics at baseline  
Baseline patient and cirrhosis characteristics of the 63 patients included in our analysis are shown 
in Table 1. The mean age was 62.3 ± 13.2 years, 54% were female and 7.9% were non-Caucasian. The 
median MELD score was 14.5 (IQR 8.0 – 20.0), and the most common etiologies of cirrhosis were non-
alcoholic steatohepatitis (33.3%), alcoholic liver disease (22.2%), hepatitis C (14.3%), and primary 
sclerosing cholangitis (11.1%). Twenty-four subjects presented with decompensated cirrhosis; among 
these patients, 36.5%  had ascites, 38.1% varices, 11.1% had history of variceal hemorrhage, and 20.6% 
HE. Some patient were prescribed cirrhosis-related medications at the time of FMT, which included 
lactulose (15.9%), rifaximin (23.8%) for HE, and antibiotics for SBP prophylaxis (9.5%).  
The majority of patients had non-severe CDI and RCDI was the primary indication for FMT 
(87.3%). Only a fraction of patients had severe CDI (9.5%) or fulminant CDI (3.2%). Complications due 
to CDI were rare: ileus (3.2%), toxic megacolon (1.6%), and colectomy (1.6%). The median number of 
prior CDI episodes was 3.0 (IQR 3.0 – 5.0) and the median number of CDI-related hospitalizations prior 
to FMT was 1.0 (0.0 – 2.0), with 55.6% of patients previously admitted due to CDI.  
 
FMT characteristics 
FMT-related characteristics are shown in Table 2. The majority of FMTs were performed as 
outpatient (76.8%), were delivered via colonoscopy (93.7%), used frozen stool (81%), and mainly derived 
from undirected donor material (39.7% stool bank, 55.6% center-based universal donor program, 4.8% 




FMT cure rates 
 The overall rate of FMT success for CDI treatment was 85.7% (54/63) (Figure 1), 87.3% 
(48/55) for recurrent CDI and 75% (6/8) for severe or fulminant CDI. Among the 9 patients who failed 
the first FMT, five experienced early FMT failure (<4 weeks from FMT), 4/5 were inpatients, and 2/5 had 
severe CDI. All four of the late FMT failures (>4 weeks from FMT) had RCDI and were treated 
outpatient. Eight of these nine patients (88.9%) of these patients achieved cure with subsequent FMT(s). 
Therefore, overall cure was 98.4% (62/63). A single patient with severe CDI and decompensated cirrhosis 
(MELD 18, Child-Pugh C) received 3 FMTs and was receiving a course of oral vancomycin for RCDI 8 
weeks after index FMT.  
Upon comparison of FMT success to FMT failures,  there were no significant differences in most 
baseline characteristics, with some notable exceptions including Child Pugh scores, pseudomembranous 
colitis, use of non-CDI antibiotics, use of probiotics at time of FMT, and inpatient status. Specifically, 
37.7% (20/54) of FMT successes and 100% (9/9) of FMT failures had Child-Pugh B/C cirrhosis 
(p<0.001). Pseudomembranous colitis at time of index FMT was observed in 0 patients who had FMT 
success  and in 22.2%(2/9) of FMT failures (p= 0.018). Non-CDI antibiotic use at time of FMT was 
present in 5.6% (3/54) of FMT successes and in 44.4% (4/9) of FMT failures (p<0.001), and probiotic had 
been administered in 24.1% (13/54) of FMT successes and in 77.8% (7/9) of FMT failures (p= 0.003). 
Finally, FMT successes were less likely to receive FMT as inpatients than FMT failures (19.0% vs 45.5%, 
p= 0.039).  
 
Patient characteristics associated with FMT failure 
 Based on the forward stepwise selection model, two patient characteristics were associated with 
FMT failure at 8 weeks. The odds of FMT failure for patients who used non-CDI antibiotics at time of 
FMT was 17.43 times the odds for those who did not use non-CDI antibiotics (95% CI: 2.00-152.03; P = 
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0.01).  The use of probiotics immediately prior to FMT was associated with an approximately 12-fold 
greater odds of FMT failure (OR=11.9, 95% CI: 1.81-78.3; P=0.01). 
 
Adverse events 
 Thirty (47.6%) patients had at least one non-severe adverse event (Table 3). AEs related or 
possibly related to FMT occurred in 30.2% (19/63) of patients, and consisted of abdominal pain/cramping 
or diarrhea after FMT. An additional 17.5% (11/63) of patients had an AE unrelated to FMT. 
 The overall rate of SAEs was 17.4% (11/63). Five of these (7.9%) were classified as possibly 
related to FMT. These included hospitalizations related to a Crohn’s flare, fecal urgency, and dehydration 
with acute kidney injury. The other two events represented hepatic decompensation possibly related to 
FMT; one patient experienced worsening HE 2 months after FMT while another patient with known PHG 
was admitted for melena and anemia found related to PHG based on esophagogastroduodenoscopy. The 





 To our knowledge, this is the largest study of cirrhosis patients treated with FMT. In this cohort, 
FMT had a similar success rate for RCDI and therapy-refractory severe CDI as previously reported in 
systematic reviews and meta-analyses of non-cirrhotic CDI patients.15,18,19 Specifically, 87.3% of patients 
were cured of RCDI, and 75% of severe/fulminant CDI after a single FMT. Among nine patients who 
failed a single FMT, eight were successfully treated with subsequent FMT(s) ± anti-CDI antibiotic 
therapy. Our results are similar to a previously reported cure rate of 87% in 14 patients with cirrhosis, 
however, FMT success in that study was defined as resolution of diarrheal symptoms within 7 days of 
FMT.20  
In this series, use of non-CDI antibiotics (which excludes rifaximin and antibiotics for SBP 
prophylaxis) at time of FMT was associated with FMT failure on multivariable analysis, a finding 
previously demonstrated in patients without cirrhosis.15,19,21 SBP prophylaxis did not impact FMT 
outcome, though the agent used and frequency of administration differed between patients and across 
sites. Further studies on use of antibiotics for SBP prophylaxis at time of FMT (including class, dosage, 
and frequency) are needed.  
Probiotic use was also implicated as an association to FMT failure in our study. Recent animal 
and human studies suggested that probiotics may impede spontaneous recovery of the microbiome 
following antibiotic-induced perturbation and that the ability for probiotic-derived organisms to colonize 
the colon is highly variable between individuals.22,23 Moreover, a multi-center study demonstrated that use 
of probiotics after successful FMT was associated with CDI recurrence.24 Th se studies, along with the 
IDSA guideline’s statement that there is insufficient evidence to recommend probiotics for primary 
prevention of CDI, suggests that probiotics should be avoided in patients with cirrhosis. 
On univariate analysis, significantly higher rates of FMT failure were noted in the presence of 
pseudomembranes on index FMT endoscopy and in patients with a higher Child-Pugh score. The 
proportion of patients with decompensated cirrhosis in the FMT failure group was also twice that of the 
FMT success group, though this did not reach significance.  Pseudomembranous colitis is a known 
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surrogate for severe CDI,25 and has been associated with higher rates of failure after a single FMT.15  
failure was associated with advanced stages of cirrhosis in a study by Pringle and colleagues,26 in which 
patients who required more FMT capsules for CDI cure had a higher median MELD score than cirrhotic 
patients only requiring a single FMT. 
The use of FMT in patients with cirrhosis has been controversial given the limited safety data in 
this population.9 Patients with cirrhosis frequently have dysbiosis27 and are at increased risk for 
translocation of bacteria leading to SBP, HE, and systemic infections.28-30 Previous studies of FMT for 
CDI have only included a handful of patients with cirrhosis, therefore specific conclusions about AEs 
could not be drawn. In a series of four patients with liver cirrhosis, one patient developed E. coli 
bacteremia 3 days after FMT, while another developed cholangitis and died within 7 days of FMT.31 The 
latter patient had a history of recurrent cholangitis and also received FMT via nasogastric tube. In another 
series, of which 9 patients had cirrhosis, there was no significant worsening of Child-Pugh scores after 
FMT, though specific data about adverse events was not tabulated.32 Specific AE data were collected by 
Bajaj and colleagues in a phase 1, randomized, placebo-controlled trial of FMT for HE.33 In this study, 
SAEs (defined as hospitalizations and emergency room visits) occurred in 6/10 patients who received 
placebo, and only 1/10 patients who received FMT. In a separate study comparing treatment of HE with 
FMT versus standard of care (SOC; lactulose and add-on rifaximin), long term follow up (>12 months) 
revealed SAES occurred in 8/8 patients in the SOC arm and 1/9 patients in the FMT arm.14 
Our study had higher rates of AEs (47.6% vs 26.0%) and SAEs (17.4% vs 9.2%) unrelated to 
FMT, possibly due  to our study’s sicker population of patients with underlying cirrhosis. However, rates 
of FMT-related AEs and SAEs were low in our cohort of cirrhosis patients, including no infections 
(including SBP) attributed to FMT.  The rate of FMT-related AEs was similar in our study (30.2%; 19/63) 
compared to a previous systematic review consisting of all-comers (28.5%; 310/1089).34 Notably, there 
were two SAEs representing hepatic decompensation (bleeding portal hypertensive gastropathy 23 days 
post-FMT and HE 56 days post-FMT) that were possibly related to FMT. While rates of FMT-related 
SAEs were comparable among patients with compensated cirrhosis (7.7%; 3/39) and those with 
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decompensated cirrhosis (8.3%; 2/24), clinicians will need to rigorously weigh the risks and benefits of 
utilizing FMT in those with severely decompensated cirrhosis. The ability to extrapolate safety results to 
severely decompensated cirrhotics may be limited as our study contained primarily patients with 
compensated disease, while the maximum MELD score in our cohort was 31.  
There has been significant interest in utilizing FMT to restore both functional and compositional 
aspects of the gut microbiome to reduce immune dysfunction that may underlie various liver-related 
diseases and complications.35 FMT has been effective in improving cognition and dysbiosis in patients 
with cirrhosis and recurrent hepatic encephalopathy (HE).13,36 The effects of FMT were also 
sustained >12 months, with significantly fewer episodes of HE and hospitalizations compared to a group 
of patients who were not given FMT.14 With the high rate of infection by multi-drug resistant organisms 
(MDRO) among patients with cirrhosis,37,38 and the known potential of microbial transplant to reduce 
bloodstream infections in patients with CDI,39 FMT’s potential to decrease MDRO colonization and 
subsequent infection is worth further exploration.40,41 The low frequency of SAEs observed in this 
retrospective series supports the safety of the future study of FMT in cirrhotic patients with multiple 
conditions that are potentially modifiable by FMT.  
Our study has a number of limitations. While all of our patients had liver cirrhosis, the etiology of 
liver disease and associated complications were heterogenous. As a retrospective study, no control group 
consisting of non-cirrhotic patients was present to assess baseline risk of FMT efficacy and adverse 
events. The multi-center format of this study also introduced patient-level and institution-level differences 
in the source of donor stool, technical proficiency of endoscopists, protocol for follow-up after FMT, and 
subsequent treatment approach after an initial failed FMT. The vast majority of FMTs were administered 
via colonoscopy, therefore this study is not able to determine safety of FMT via upper GI routes in 
patients with cirrhosis. Finally, our multivariable analysis to identify patient characteristics associated 
with FMT failure was limited by our small sample size and even smaller number of patients with FMT 
failure. It is possible that due to this limitation, factors associated with FMT failure were not identified by 
our study due to lack of power. We also acknowledge that as a retrospective study, selection bias could 
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have been introduced while evaluating patients for FMT candidacy due to uncertainty about the role of 
FMT in those with decompensated cirrhosis. A larger study focusing specifically on those with 
decompensated cirrhosis is necessary to further analyze this. 
Further investigation is needed to determine the optimal route of FMT delivery in patients with 
cirrhosis. Colonoscopic delivery of FMT was performed in 93.7% of our cohort. Previous experimental 
studies have demonstrated that bacteria preferentially translocates across the small bowel rather than the 
colon.42 Therefore, an upper GI route of FMT delivery could potentially increase the risk of bacterial 
translocation and associated AEs. Nevertheless, a recent prospective study utilized FMT capsules 
prepared from a single donor to treat recurrent HE, showed lower hospitalization and mortality rates in 
the FMT arm without significant safety issues.33 Rates of FMT cure in a larger cohort of liver cirrhosis 
patients with severe or fulminant CDI need to be examined. Finally, the long-term effects of FMT on 
liver-related indices including fibrosis, hepatic decompensation, infections, mortality, and liver transplant 
candidacy need to be explored.  
 In conclusion, a single FMT appears effective in the treatment of CDI in patients with cirrhosis. 
On multivariable analysis, non-CDI antibiotic and probiotic use at time of FMT was associated with FMT 
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Table 1. Patient and Cirrhosis Characteristics by FMT Outcome 
  
Total (n = 63) 
FMT outcome at 8 weeks P 
Value   Success (N = 54) Failure (N = 9) 
Age, mean (sd) 62.3 (13.2) 61.2 (12.7) 69.0 (15.1) 0.1 
Female gender 34 (54.0%) 29 (53.7%) 5 (55.6%) 1 
Non-Caucasian race 5 (7.9%) 5 (9.3%) 0 (0%) 1 
Charlson comorbidity score, mean (sd) 6.7 (2.9) 6.6 (3.0) 7.2 (2.4) 0.54 
IBD 10 (15.9%) 10 (18.5%) 0 (0%) 0.33 
Chronic dialysis 5 (7.9%) 5 (9.3%) 0 (0%) 1 
Immunosuppression 17 (27.0%) 16 (29.6%) 1 (11.1%) 0.42 
Etiology of Liver Cirrhosis       0.27 
       ETOH 14 (22.2%) 13 (24.1%) 1 (11.1%)   
       Hepatitis C 9 (14.3%) 9 (16.7%) 0 (0%)   
NASH 21 (33.3%) 16 (29.6%) 5 (55.6%)   
PSC 7 (11.1%) 7 (13.0%) 0 (0%)   
Other 12 (19.0%) 9 (16.7%) 3 (33.3%)   
Decompensated cirrhosis 24 (38.1%) 18 (33.3%) 6 (66.7%) 0.073 
History of cirrhosis-related complications         
       Ascites 23 (36.5%) 18 (33.3%) 5 (55.6%) 0.27 
       Hepatic encephalopathy 13 (20.6%) 10 (18.5%) 3 (33.3%) 0.38 
Varices 24 (38.1%) 20 (37.0%) 4 (44.4%) 0.72 
Variceal hemorrhage 7 (11.1%) 5 (9.3%) 2 (22.2%) 0.26 
Child-Pugh Score       <0.001 
A 33 (53.2%) 33 (62.3%) 0 (0%)   
       B/C 29 (46.8%) 20 (37.7%) 9 (100%)   
MELD Score, median (IQR) 14.5 (8.0 - 20.0) 13.0 (8.0 - 20.0) 18.0 (14.0 - 20.0) 0.17 
Serum sodium, median (IQR) 138.0 (135.0 - 140.0) 138.0 (135.0 - 140.0) 138.0 (134.0 - 140.0) 0.64 
Serum creatinine, median (IQR) 0.9 (0.7 - 1.6) 0.9 (0.7 - 1.5) 1.5 (0.5 - 3.0) 0.75 
White blood count, median (IQR) 5.2 (3.9 - 8.7) 5.0 (4.0 - 7.6) 6.1 (3.4 - 10.0) 0.87 
INR, median (IQR) 1.2 (1.1 - 1.4) 1.2 (1.1 - 1.4) 1.3 (1.2 - 1.4) 0.58 
Serum total bilirubin (mg/dL), median 
(IQR) 
0.7 (0.5 - 1.0) 0.7 (0.5 - 1.0) 1.0 (0.7 - 2.8) 0.11 
Platelet Count, median (IQR) 139.5 (91.0 - 213.0) 138.0 (85.0 - 215.0) 158.0 (126.0 - 172.0) 0.91 
Use of cirrhosis-related medications         
       Lactulose 10 (15.9%) 8 (14.8%) 2 (22.2%) 0.63 
       Rifaximin 15 (23.8%) 12 (22.2%) 3 (33.3%) 0.43 
       SBP prophylaxis 6 (9.5%) 4 (7.4%) 2 (22.2%) 0.2 
Indication for FMT       0.42 
       Recurrent CDI 55 (87.3%) 48 (88.9%) 7 (77.8%)   
       Severe CDI 6 (9.5%) 4 (7.4%) 2 (22.2%)   
       Fulminant CDI 2 (3.2%) 2 (3.7%) 0 (0%)   
Hypotension 7 (11.1%) 6 (11.1%) 1 (11.1%) 1 
Ileus 2 (3.2%) 2 (3.7%) 0 (0%) 1 
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Toxic megacolon 1 (1.6%) 1 (1.9%) 0 (0%) 1 
Colectomy due to CDI 1 (1.6%) 1 (1.9%) 0 (0%) 1 
Number of CDI episodes prior to FMT, 
median (IQR) 
3.0 (3.0 - 5.0) 3.0 (3.0 - 5.0) 4.0 (3.0 - 6.0) 0.45 
Number of CDI-related hospitalizations 
prior to FMT, median (IQR) 
1.0 (0.0 - 2.0) 1.0 (0.0 - 1.0) 2.0 (1.0 - 2.0) 0.11 
CDIFF related hospitalizations prior to FMT 35 (55.6%) 28 (51.9%) 7 (77.8%) 0.28 
 
Abbreviations: CDI, Clostridioides difficile infection; FMT, fecal microbiota transplantation; IBD, 
inflammatory bowel disease; IQR, interquartile range; NASH, non-alcoholic steatohepatitis; MELD, 
model for end-stage liver disease; PSC, primary sclerosing cholangitis; SBP, spontaneous bacterial 




Table 2. Clostridioides difficile Infection and Fecal Microbiota Transplantation Characteristics by 
FMT Outcome 
  
Total (n = 63) 
FMT outcome at 8 weeks 
P Value 
  Success (N = 54) Failure (N = 9) 
Inpatient FMT 16 (23.2%) 11 (19.0%) 5 (45.5%) 0.039 
Presence of pseudomembranes at first FMT 2 (3.2%) 0 (0%) 2 (22.2%) 0.018 
Donor type       0.67 
       Patient selected 3 (4.8%) 3 (5.6%) 0 (0%)   
       Universal donor 35 (55.6%) 31 (57.4%) 4 (44.4%)   
       Stool bank 25 (39.7%) 20 (37.0%) 5 (55.6%)   
Stool type       1 
       Fresh 11 (17.5%) 10 (18.5%) 1 (11.1%)   
       Frozen 51 (81.0%) 43 (79.6%) 8 (88.9%)   
       Lyophylized 1 (1.6%) 1 (1.9%) 0 (0%)   
FMT delivery method       0.47 
       Capsule 3 (4.8%) 2 (3.7%) 1 (11.1%)   
       Colonoscopy 59 (93.7%) 51 (94.4%) 8 (88.9%)   
       PEG 1 (1.6%) 1 (1.9%) 0 (0%)   
Probiotic use prior to FMT 20 (31.7%) 13 (24.1%) 7 (77.8%) 0.003 
Non-CDI antibiotics use at time of FMT 7 (11.1%) 3 (5.6%) 4 (44.4%) <0.001 
CDI antibiotics use in 7 days prior to FMT 44 (69.8%) 38 (70.4%) 6 (66.7%) 1 
Non-CDI antibiotics use in 8 weeks post 
FMT 
11 (17.5%) 10 (18.5%) 1 (11.1%) 1 
Abbreviations: CDI, Clostridioides difficile infection; FMT, fecal microbiota transplantation; IQR, 
interquartile range; PEG, percutaneous endoscopic gastrostomy. 
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Table 3. Adverse Events Related and Unrelated to FMT During 12-Week Follow-Up. 
 
  #of patients 
(N = 63) 
AE related to FMT   
No 44 
Yes (abdominal pain/cramping, N = 10; FMT-related diarrhea (N = 
9) 19 
AE unrelated to FMT   
No 52 
Yes (chronic diarrhea despite negative CDI testing, N = 4; diarrhea 
due to underlying Crohn’s disease, N = 1; abdominal pain; back 
pain; cellulitis; fever/chills; anemia; fatigue) 
11 
Serious AE related to FMT   
No 58 
Yes (hospitalizations for Crohn’s disease flare, fecal urgency, 
AKI/dehydration post-procedure, hepatic encephalopathy, portal 
hypertensive bleed). 
5 
Serious AE unrelated to FMT   
No 57 
Yes (transition to hospice; hospitalizations for pneumonia (N = 2), 
sepsis due to leg cellulitis, recurrent CDI, hyperglycemia). 6 
Abbreviations: AE, adverse event; AKI, acute kidney injury; CDI, Clostridioides difficile infection; FMT, 
fecal microbiota transplant; GI, gastrointestinal. 
 
 
